Skip to main content
Top
Published in: Inflammation 4/2019

01-08-2019 | Idiopathic Pulmonary Fibrosis | REVIEW

Acute Lung Injury: IL-17A-Mediated Inflammatory Pathway and Its Regulation by Curcumin

Authors: Mahesh Manjunath Gouda, Yashodhar Prabhakar Bhandary

Published in: Inflammation | Issue 4/2019

Login to get access

Abstract

Acute lung injury (ALI) is characterized by acute inflammation and tissue injury results in dysfunction of the alveolar epithelial membrane. If the epithelial injury is severe, a fibroproliferative phase of ALI can develop. During this phase, the activated fibroblast and myofibroblasts synthesize excessive collagenous extracellular matrix that leads to a condition called pulmonary fibrosis. Lung injury can be caused by several ways; however, the present review focus on bleomycin (BLM)-mediated changes in the pathology of lungs. BLM is a chemotherapeutic agent and has toxic effects on lungs, which leads to oxidative damage and elaboration of inflammatory cytokines. In response to the injury, the inflammatory cytokines will be activated to defend the system from injury. These cytokines along with growth factors stimulate the proliferation of myofibroblasts and secretion of pathologic extracellular matrix. During BLM injury, the pro-inflammatory cytokine such as IL-17A will be up-regulated and mediates the inflammation in the alveolar epithelial cell and also brings about recruitment of certain inflammatory cells in the alveolar surface. These cytokines probably help in up-regulating the expression of p53 and fibrinolytic system molecules during the alveolar epithelial cells apoptosis. Here, our key concern is to provide the adequate knowledge about IL-17A-mediated p53 fibrinolytic system and their pathogenic progression to pulmonary fibrosis. The present review focuses mainly on IL-17A-mediated p53-fibrinolytic aspects and how curcumin is involved in the regulation of pathogenic progression of ALI and pulmonary fibrosis.
Literature
2.
go back to reference Ricard, J.D., D. Dreyfuss, and G. Saumon. 2001. Production of inflammatory cytokines in ventilator-induced lung injury: A reappraisal. American Journal of Respiratory and Critical Care Medicine 163: 1176–1180.CrossRef Ricard, J.D., D. Dreyfuss, and G. Saumon. 2001. Production of inflammatory cytokines in ventilator-induced lung injury: A reappraisal. American Journal of Respiratory and Critical Care Medicine 163: 1176–1180.CrossRef
3.
go back to reference Wei, J., and D. Chen. 2013. IL-17 cytokines in immunity and inflammation. Emerging Microbes and Infections 60: 1–5. Wei, J., and D. Chen. 2013. IL-17 cytokines in immunity and inflammation. Emerging Microbes and Infections 60: 1–5.
4.
go back to reference Shaikh, P. 2011. Cytokines and their physiologic and pharmacologic functions in inflammation: A review. International Journal of Pharmacy and Life Sciences 11: 1247–1263. Shaikh, P. 2011. Cytokines and their physiologic and pharmacologic functions in inflammation: A review. International Journal of Pharmacy and Life Sciences 11: 1247–1263.
5.
go back to reference Standiford, T.J., S.L. Kunkel, S.H. Phan, et al. 1991. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. Journal of Biological Chemistry 266: 9912–9918.PubMed Standiford, T.J., S.L. Kunkel, S.H. Phan, et al. 1991. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. Journal of Biological Chemistry 266: 9912–9918.PubMed
6.
go back to reference Chung, K. 2001. Cytokines in chronic obstructive pulmonary disease. European Respiratory Journal 18: 50–59.CrossRef Chung, K. 2001. Cytokines in chronic obstructive pulmonary disease. European Respiratory Journal 18: 50–59.CrossRef
7.
go back to reference Funke, M., and T. Geiser. 2015. Idiopathic pulmonary fibrosis: The turning point is now! Swiss Medical Weekly 145: 14139. Funke, M., and T. Geiser. 2015. Idiopathic pulmonary fibrosis: The turning point is now! Swiss Medical Weekly 145: 14139.
8.
go back to reference Juarez, M.M., A.L. Chan, A.G. Norris, et al. 2015. Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. Journal of Thoracic Disease 7: 499.PubMedPubMedCentral Juarez, M.M., A.L. Chan, A.G. Norris, et al. 2015. Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. Journal of Thoracic Disease 7: 499.PubMedPubMedCentral
9.
go back to reference Goss, C.H., R.G. Brower, L.D. Hudson, et al. 2003. Incidence of acute lung injury in the United States. Critical Care Medicine 31: 1607–1611.CrossRef Goss, C.H., R.G. Brower, L.D. Hudson, et al. 2003. Incidence of acute lung injury in the United States. Critical Care Medicine 31: 1607–1611.CrossRef
10.
go back to reference Nalysnyk, L., J. Cid-Ruzafa, P. Rotella, et al. 2012. Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. European Respiratory Review 21: 355–361.CrossRef Nalysnyk, L., J. Cid-Ruzafa, P. Rotella, et al. 2012. Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. European Respiratory Review 21: 355–361.CrossRef
11.
go back to reference Smith, M.R., S.R. Gangireddy, V.R. Narala, et al. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 298: 616–625. Smith, M.R., S.R. Gangireddy, V.R. Narala, et al. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 298: 616–625.
12.
go back to reference Hay, J., S. Shahzeidi, and G. Laurent. 1991. Mechanisms of bleomycin-induced lung damage. Archives of Toxicology 65: 81–94.CrossRef Hay, J., S. Shahzeidi, and G. Laurent. 1991. Mechanisms of bleomycin-induced lung damage. Archives of Toxicology 65: 81–94.CrossRef
13.
go back to reference Tomas, R., S. Clarissa, and A. Fredarico. 2013. Review article on bleomycin induced lung injury. Cancer Research 1–9. Tomas, R., S. Clarissa, and A. Fredarico. 2013. Review article on bleomycin induced lung injury. Cancer Research 1–9.
14.
go back to reference Liang, Y., J. Liu, and Z. Feng. 2013. The regulation of cellular metabolism by tumor suppressor p53. Cell & Bioscience 3: 1–9.CrossRef Liang, Y., J. Liu, and Z. Feng. 2013. The regulation of cellular metabolism by tumor suppressor p53. Cell & Bioscience 3: 1–9.CrossRef
15.
go back to reference Nevins, W., G. Irina, and P. Sergei. 2012. Molecular and cellular mechanism of pulmonary fibrosis. Fibrogenesis & Tissue Repair 5: 1–11.CrossRef Nevins, W., G. Irina, and P. Sergei. 2012. Molecular and cellular mechanism of pulmonary fibrosis. Fibrogenesis & Tissue Repair 5: 1–11.CrossRef
16.
go back to reference Xiaopeng, L., S. Ruijie, F. Gerasimos, et al. 2004. Apoptosis in lung injury and remodeling. Journal of Applied Physiology 97: 1535–1542.CrossRef Xiaopeng, L., S. Ruijie, F. Gerasimos, et al. 2004. Apoptosis in lung injury and remodeling. Journal of Applied Physiology 97: 1535–1542.CrossRef
17.
go back to reference Kuwano, K., N. Hagimoto, and Y. Nakanishi. 2004. The role of apoptosis in pulmonary fibrosis. Journal of Histology and Histopathology 19: 867–881.PubMed Kuwano, K., N. Hagimoto, and Y. Nakanishi. 2004. The role of apoptosis in pulmonary fibrosis. Journal of Histology and Histopathology 19: 867–881.PubMed
18.
go back to reference Bhandary, Y.P., T. Velusamy, P. Shetty, et al. 2009. Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. American Journal of Respiratory and Critical Care Medicine 179: 288–298.CrossRef Bhandary, Y.P., T. Velusamy, P. Shetty, et al. 2009. Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. American Journal of Respiratory and Critical Care Medicine 179: 288–298.CrossRef
19.
go back to reference Pitt, B., and L. andOrtiz. 2004. Stemcells in lungbiology. American Journal of Physiology. Lung Cellular and Molecular Physiology 286: 621–623.CrossRef Pitt, B., and L. andOrtiz. 2004. Stemcells in lungbiology. American Journal of Physiology. Lung Cellular and Molecular Physiology 286: 621–623.CrossRef
20.
go back to reference Chow, L.N., P. Schreiner, B.Y. Ng, et al. 2016. Impact of a CXCL12/CXCR4 antagonist in bleomycin (BLM) induced pulmonary fibrosis and carbon tetrachloride (CCL4) induced hepatic fibrosis in mice. PLoS One 11: e0151765.CrossRef Chow, L.N., P. Schreiner, B.Y. Ng, et al. 2016. Impact of a CXCL12/CXCR4 antagonist in bleomycin (BLM) induced pulmonary fibrosis and carbon tetrachloride (CCL4) induced hepatic fibrosis in mice. PLoS One 11: e0151765.CrossRef
21.
go back to reference Yehualaeshet, T., R. O'Connor, J. Green-Johnson, et al. 1999. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. American Journal of Pathology 155: 841–851.CrossRef Yehualaeshet, T., R. O'Connor, J. Green-Johnson, et al. 1999. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. American Journal of Pathology 155: 841–851.CrossRef
22.
go back to reference Shi, K., J. Jiang, T. Ma, et al. 2014. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respiratory Physiology & Neurobiology 190: 113–117.CrossRef Shi, K., J. Jiang, T. Ma, et al. 2014. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respiratory Physiology & Neurobiology 190: 113–117.CrossRef
23.
go back to reference Luzina, I.G., P. Kopach, and V. Lockatell. 2013. Interleukin-33 potentiates bleomycin-induced lung injury. American Journal of Respiratory Cell and Molecular Biology 49: 999–1008.CrossRef Luzina, I.G., P. Kopach, and V. Lockatell. 2013. Interleukin-33 potentiates bleomycin-induced lung injury. American Journal of Respiratory Cell and Molecular Biology 49: 999–1008.CrossRef
24.
go back to reference Venkatesan, N., V. Punithavathi, and G. Chandrakasan. 1997. Curcumin protects bleomycin-induced lung injury in rats. Life Sciences 61: A51–A58.CrossRef Venkatesan, N., V. Punithavathi, and G. Chandrakasan. 1997. Curcumin protects bleomycin-induced lung injury in rats. Life Sciences 61: A51–A58.CrossRef
25.
go back to reference Tsai, H.C., S. Velichko, L.Y. Hung, et al. 2013. IL-17A and Th17 cells in lung inflammation: An update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clinical and Developmental Immunology 1: 1–12.CrossRef Tsai, H.C., S. Velichko, L.Y. Hung, et al. 2013. IL-17A and Th17 cells in lung inflammation: An update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clinical and Developmental Immunology 1: 1–12.CrossRef
26.
go back to reference Bozinovski, S., H.J. Seow, S.P. Chan, et al. 2015. Innate cellular sources of interleukin-17A regulate macrophage accumulation in cigarette-smoke-induced lung inflammation in mice. Clinical Science 129: 785–796.CrossRef Bozinovski, S., H.J. Seow, S.P. Chan, et al. 2015. Innate cellular sources of interleukin-17A regulate macrophage accumulation in cigarette-smoke-induced lung inflammation in mice. Clinical Science 129: 785–796.CrossRef
27.
go back to reference Banerjee, S., J. Ninkovic, J. Meng, et al. 2015. Morphine compromises bronchial epithelial TLR2/IL17R signaling crosstalk, necessary for lung IL17 homeostasis. Scientific Reports 5: 1–17.CrossRef Banerjee, S., J. Ninkovic, J. Meng, et al. 2015. Morphine compromises bronchial epithelial TLR2/IL17R signaling crosstalk, necessary for lung IL17 homeostasis. Scientific Reports 5: 1–17.CrossRef
28.
go back to reference Conte, E., M. Iemmolo, E. Fagone, et al. 2014. Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. Journal of Immunology 219: 425–431. Conte, E., M. Iemmolo, E. Fagone, et al. 2014. Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. Journal of Immunology 219: 425–431.
29.
go back to reference Tan, H., and M. Rosenthal. 2013. IL-17 in lung disease: Friend or foe? Thorax 68: 788–790.CrossRef Tan, H., and M. Rosenthal. 2013. IL-17 in lung disease: Friend or foe? Thorax 68: 788–790.CrossRef
30.
go back to reference Bai, L., and W. Zhu. 2006. p53: Structure, Function and Therapeutic Applications. Journal of Cancer Molecules 2: 141–153. Bai, L., and W. Zhu. 2006. p53: Structure, Function and Therapeutic Applications. Journal of Cancer Molecules 2: 141–153.
31.
go back to reference Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2011. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. American Journal of Physiology. Lung Cellular and Molecular Physiology 302: 463–473.CrossRef Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2011. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. American Journal of Physiology. Lung Cellular and Molecular Physiology 302: 463–473.CrossRef
32.
go back to reference Marudamuthu, A.S., Y.P. Bhandary, S.K. Shetty, J. Fu, V. Sathish, Y.S. Prakash, and S. Shetty. 2015. Role of the urokinase-fibrinolytic system in epithelial–mesenchymal transition during lung injury. The American Journal of Pathology 185: 55–68.CrossRef Marudamuthu, A.S., Y.P. Bhandary, S.K. Shetty, J. Fu, V. Sathish, Y.S. Prakash, and S. Shetty. 2015. Role of the urokinase-fibrinolytic system in epithelial–mesenchymal transition during lung injury. The American Journal of Pathology 185: 55–68.CrossRef
33.
go back to reference Li, C., P. Yang, Y. Sun, et al. 2012. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza a (H1N1) virus. Cell Research 2: 528–538.CrossRef Li, C., P. Yang, Y. Sun, et al. 2012. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza a (H1N1) virus. Cell Research 2: 528–538.CrossRef
34.
go back to reference Ge, S., B. Hertel, N. Susnik, et al. 2014. Interleukin 17 receptor a modulates monocyte subsets and macrophage generation in vivo. PLoS One 9: 1–10. Ge, S., B. Hertel, N. Susnik, et al. 2014. Interleukin 17 receptor a modulates monocyte subsets and macrophage generation in vivo. PLoS One 9: 1–10.
35.
go back to reference Cheng, D.S., W. Han, S.M. Chen, et al. 2007. Airway epithelium controls lung inflammation and injury through the NF-κB pathway. Journal of Immunology 178: 6504–6513.CrossRef Cheng, D.S., W. Han, S.M. Chen, et al. 2007. Airway epithelium controls lung inflammation and injury through the NF-κB pathway. Journal of Immunology 178: 6504–6513.CrossRef
36.
go back to reference Sutton, C.E., L.A. Mielke, and K.H. Mills. 2012. IL-17-producing γδ T cells and innate lymphoid cells. European Journal of Immunology 42: 2221–2231.CrossRef Sutton, C.E., L.A. Mielke, and K.H. Mills. 2012. IL-17-producing γδ T cells and innate lymphoid cells. European Journal of Immunology 42: 2221–2231.CrossRef
37.
go back to reference Oh, K., H.B. Park, O.J. Byoun, D.M. Shin, E.M. Jeong, Y.W. Kim, Y.S. Kim, G. Melino, I.G. Kim, and D.S. Lee. 2011. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. Journal of Experimental Medicine 208: 1707–1719.CrossRef Oh, K., H.B. Park, O.J. Byoun, D.M. Shin, E.M. Jeong, Y.W. Kim, Y.S. Kim, G. Melino, I.G. Kim, and D.S. Lee. 2011. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. Journal of Experimental Medicine 208: 1707–1719.CrossRef
38.
go back to reference Mi, S., Z. Li, H.Z. Yang, H. Liu, J.P. Wang, Y.G. Ma, X.X. Wang, H.Z. Liu, W. Sun, and Z.W. Hu. 2011. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-β1–dependent and independent mechanisms. Journal of Immunology 187: 3003–3014.CrossRef Mi, S., Z. Li, H.Z. Yang, H. Liu, J.P. Wang, Y.G. Ma, X.X. Wang, H.Z. Liu, W. Sun, and Z.W. Hu. 2011. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-β1–dependent and independent mechanisms. Journal of Immunology 187: 3003–3014.CrossRef
39.
go back to reference Gasse, P., N. Riteau, R. Vacher, M.L. Michel, A. Fautrel, F. di Padova, L. Fick, S. Charron, V. Lagente, G. Eberl, M. le Bert, V.F.J. Quesniaux, F. Huaux, M. Leite-de-Moraes, B. Ryffel, and I. Couillin. 2011. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 6: e23185.CrossRef Gasse, P., N. Riteau, R. Vacher, M.L. Michel, A. Fautrel, F. di Padova, L. Fick, S. Charron, V. Lagente, G. Eberl, M. le Bert, V.F.J. Quesniaux, F. Huaux, M. Leite-de-Moraes, B. Ryffel, and I. Couillin. 2011. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 6: e23185.CrossRef
40.
go back to reference Wilson, M.S., S.K. Madala, T.R. Ramalingam, et al. 2010. Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent. Journal of Experimental Medicine 207: 535–552.CrossRef Wilson, M.S., S.K. Madala, T.R. Ramalingam, et al. 2010. Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent. Journal of Experimental Medicine 207: 535–552.CrossRef
41.
go back to reference Florova, G., A. Azghani, S. Karandashova, et al. 2015. Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. American Journal of Respiratory Cell and Molecular Biology 52: 429–437.CrossRef Florova, G., A. Azghani, S. Karandashova, et al. 2015. Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. American Journal of Respiratory Cell and Molecular Biology 52: 429–437.CrossRef
42.
go back to reference Madhyastha, R., H. Madhyastha, Y. Nakajima, et al. 2009. Curcumin facilitates fibrinolysis and cellular migration during wound healing by modulating urokinase plasminogen activator expression. Pathophysiology of Haemostasis and Thrombosis 10: 59–66.CrossRef Madhyastha, R., H. Madhyastha, Y. Nakajima, et al. 2009. Curcumin facilitates fibrinolysis and cellular migration during wound healing by modulating urokinase plasminogen activator expression. Pathophysiology of Haemostasis and Thrombosis 10: 59–66.CrossRef
43.
go back to reference Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2013. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. American Journal of Pathology 183: 131–143.CrossRef Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2013. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. American Journal of Pathology 183: 131–143.CrossRef
44.
go back to reference Phan, S. 2008. Biology of fibroblasts and Myofibroblasts. Proceedings of the American Thoracic Society 5: 334–337.CrossRef Phan, S. 2008. Biology of fibroblasts and Myofibroblasts. Proceedings of the American Thoracic Society 5: 334–337.CrossRef
45.
go back to reference Kim, H.S., H. Go, S. Akira, and D.H. Chung. 2011. TLR2-mediated production of IL-27 and chemokines by respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in mice. Journal of Immunology 187: 4007–4017.CrossRef Kim, H.S., H. Go, S. Akira, and D.H. Chung. 2011. TLR2-mediated production of IL-27 and chemokines by respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in mice. Journal of Immunology 187: 4007–4017.CrossRef
46.
go back to reference Zhang, Y., and N. Kaminski. 2012. Biomarkers in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine 18: 441–446.CrossRef Zhang, Y., and N. Kaminski. 2012. Biomarkers in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine 18: 441–446.CrossRef
47.
go back to reference Grotendorst, G.R., H. Rahmanie, and M.R. Duncan. 2004. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB Journal 18: 469–479.CrossRef Grotendorst, G.R., H. Rahmanie, and M.R. Duncan. 2004. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB Journal 18: 469–479.CrossRef
48.
go back to reference Ahluwalia, N., B.S. Shea, and A.M. Tager. 2014. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. American Journal of Respiratory and Critical Care Medicine 190: 867–878.CrossRef Ahluwalia, N., B.S. Shea, and A.M. Tager. 2014. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. American Journal of Respiratory and Critical Care Medicine 190: 867–878.CrossRef
49.
go back to reference Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2015. Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza a virus infection-induced lung injury. PLoS One 10: 1–12.CrossRef Bhandary, Y.P., S.K. Shetty, A.S. Marudamuthu, et al. 2015. Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza a virus infection-induced lung injury. PLoS One 10: 1–12.CrossRef
50.
go back to reference Tucker, T.A., A. Jeffers, A. Alvarez, et al. 2014. Plasminogen activator Inhibitor-1 deficiency augments visceral mesothelial organization, Intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin–induced pleural injury. American Journal of Respiratory Cell and Molecular Biology 50: 316–327.PubMedPubMedCentral Tucker, T.A., A. Jeffers, A. Alvarez, et al. 2014. Plasminogen activator Inhibitor-1 deficiency augments visceral mesothelial organization, Intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin–induced pleural injury. American Journal of Respiratory Cell and Molecular Biology 50: 316–327.PubMedPubMedCentral
51.
go back to reference Shetty, S., J. Padijnayayveetil, T. Tucker, et al. 2008. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. American Journal of Physiology. Lung Cellular and Molecular Physiology 295: 967–975.CrossRef Shetty, S., J. Padijnayayveetil, T. Tucker, et al. 2008. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. American Journal of Physiology. Lung Cellular and Molecular Physiology 295: 967–975.CrossRef
52.
go back to reference Marudamuthu, A.S., S.K. Shetty, Y.P. Bhandary, S. Karandashova, M. Thompson, V. Sathish, G. Florova, T.B. Hogan, C.M. Pabelick, Y.S. Prakash, Y. Tsukasaki, J. Fu, M. Ikebe, S. Idell, and S. Shetty. 2015. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. Journal of Biological Chemistry 290: 9428–9441.CrossRef Marudamuthu, A.S., S.K. Shetty, Y.P. Bhandary, S. Karandashova, M. Thompson, V. Sathish, G. Florova, T.B. Hogan, C.M. Pabelick, Y.S. Prakash, Y. Tsukasaki, J. Fu, M. Ikebe, S. Idell, and S. Shetty. 2015. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. Journal of Biological Chemistry 290: 9428–9441.CrossRef
53.
go back to reference Shetty, S.K., N. Tiwari, A.S. Marudamuthu, et al. 2017. p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. American Journal of Pathology 187: 1016–1034.CrossRef Shetty, S.K., N. Tiwari, A.S. Marudamuthu, et al. 2017. p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. American Journal of Pathology 187: 1016–1034.CrossRef
54.
go back to reference Puthusseri, B., A. Marudamuthu, N. Tiwari, J. Fu, S. Idell, and S. Shetty. 2017. Regulation of p53-mediated changes in the uPA-fibrinolytic system and in lung injury by loss of surfactant protein C expression in alveolar epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 312: L783–L796.CrossRef Puthusseri, B., A. Marudamuthu, N. Tiwari, J. Fu, S. Idell, and S. Shetty. 2017. Regulation of p53-mediated changes in the uPA-fibrinolytic system and in lung injury by loss of surfactant protein C expression in alveolar epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 312: L783–L796.CrossRef
55.
go back to reference Boyanapalli, S.S., and A.N. Kong. 2015. “Curcumin, the king of spices”: Epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Current Pharmacology Reports 1: 129–139.CrossRef Boyanapalli, S.S., and A.N. Kong. 2015. “Curcumin, the king of spices”: Epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Current Pharmacology Reports 1: 129–139.CrossRef
56.
go back to reference Zhang, Y., D. Liang, L. Dong, et al. 2015. Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respiratory Research 16: 1–13.CrossRef Zhang, Y., D. Liang, L. Dong, et al. 2015. Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respiratory Research 16: 1–13.CrossRef
57.
go back to reference Zhang, D., C. Huang, C. Yang, et al. 2011. Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respiratory Research 12: 1–12.CrossRef Zhang, D., C. Huang, C. Yang, et al. 2011. Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respiratory Research 12: 1–12.CrossRef
58.
go back to reference Moghaddam, S.J., P. Barta, S.G. Mirabolfathinejad, Z. Ammar-Aouchiche, N.T. Garza, T.T. Vo, R.A. Newman, B.B. Aggarwal, C.M. Evans, M.J. Tuvim, R. Lotan, and B.F. Dickey. 2009. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Journal of Carcinogenesis 30: 1949–1956.CrossRef Moghaddam, S.J., P. Barta, S.G. Mirabolfathinejad, Z. Ammar-Aouchiche, N.T. Garza, T.T. Vo, R.A. Newman, B.B. Aggarwal, C.M. Evans, M.J. Tuvim, R. Lotan, and B.F. Dickey. 2009. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Journal of Carcinogenesis 30: 1949–1956.CrossRef
59.
go back to reference Helal, M.H., N.S. Ahmed, M.S. Elwessaly, et al. 2013. Synthesis, characterization, and antioxidant and bleomycin-dependent DNA damage evaluation of curcumin analogs. Archiv der Pharmazie - Chemistry in Life Sciences 347: 123–133.CrossRef Helal, M.H., N.S. Ahmed, M.S. Elwessaly, et al. 2013. Synthesis, characterization, and antioxidant and bleomycin-dependent DNA damage evaluation of curcumin analogs. Archiv der Pharmazie - Chemistry in Life Sciences 347: 123–133.CrossRef
60.
go back to reference King, T., M. Schwrz, K. Brown, et al. 2001. Idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 164: 1025–1032.CrossRef King, T., M. Schwrz, K. Brown, et al. 2001. Idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 164: 1025–1032.CrossRef
61.
go back to reference Onodera, T., I. Kuriyama, T. Andoh, et al. 2015. Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-allergic activities of a curcumin lipid nanoemulsion. International Journal of Molecular Medicine 35: 1720–1728.CrossRef Onodera, T., I. Kuriyama, T. Andoh, et al. 2015. Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-allergic activities of a curcumin lipid nanoemulsion. International Journal of Molecular Medicine 35: 1720–1728.CrossRef
62.
go back to reference Katsori, A.M., A. Palagani, N. Bougarne, D. Hadjipavlou-Litina, G. Haegeman, and W. vanden Berghe. 2015. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue. Molecules 20: 863–878.CrossRef Katsori, A.M., A. Palagani, N. Bougarne, D. Hadjipavlou-Litina, G. Haegeman, and W. vanden Berghe. 2015. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue. Molecules 20: 863–878.CrossRef
63.
go back to reference Aggarwal, B., L. Deb, and S. Prasad. 2014. Curcumin differs from Tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules 20: 185–205.CrossRef Aggarwal, B., L. Deb, and S. Prasad. 2014. Curcumin differs from Tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules 20: 185–205.CrossRef
64.
go back to reference Zingg, J.M., S.T. Hasan, and M. Meydani. 2013. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 39: 101–121.CrossRef Zingg, J.M., S.T. Hasan, and M. Meydani. 2013. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 39: 101–121.CrossRef
65.
go back to reference Guzel, A., M. Kanter, A. Guzel, et al. 2013. Protective effect of curcumin on acute lung injury induced by intestinal ischaemia/reperfusion. Toxicology and Industrial Health 29: 633–642.CrossRef Guzel, A., M. Kanter, A. Guzel, et al. 2013. Protective effect of curcumin on acute lung injury induced by intestinal ischaemia/reperfusion. Toxicology and Industrial Health 29: 633–642.CrossRef
66.
go back to reference Lian, Q., X. Li, Y. Shang, et al. 2006. Protective effect of curcumin on endotoxin-induced acute lung injury in rats. Journal of Huazhong University of Science and Technology. Medical Sciences 26: 678–681.CrossRef Lian, Q., X. Li, Y. Shang, et al. 2006. Protective effect of curcumin on endotoxin-induced acute lung injury in rats. Journal of Huazhong University of Science and Technology. Medical Sciences 26: 678–681.CrossRef
67.
go back to reference Punithavathi, D., N. Venkatesan, and M. Babu. 2000. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 131: 169–172.CrossRef Punithavathi, D., N. Venkatesan, and M. Babu. 2000. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 131: 169–172.CrossRef
69.
go back to reference Gouda, M.M., A. Prabhu, and Y.P. Bhandary. 2018. Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells. Journal of Cellular Biochemistry 119: 2222–2230.CrossRef Gouda, M.M., A. Prabhu, and Y.P. Bhandary. 2018. Curcumin alleviates IL-17A-mediated p53-PAI-1 expression in bleomycin-induced alveolar basal epithelial cells. Journal of Cellular Biochemistry 119: 2222–2230.CrossRef
70.
go back to reference Anand, P., A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal. 2007. Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 4: 807–818.CrossRef Anand, P., A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal. 2007. Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 4: 807–818.CrossRef
71.
go back to reference Purpura, M., R.P. Lowery, J.M. Wilson, H. Mannan, G. Münch, and V. Razmovski-Naumovski. 2018. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. European Journal of Nutrition 57: 929–938.CrossRef Purpura, M., R.P. Lowery, J.M. Wilson, H. Mannan, G. Münch, and V. Razmovski-Naumovski. 2018. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. European Journal of Nutrition 57: 929–938.CrossRef
72.
go back to reference Peng, S., Z. Li, L. Zou, W. Liu, C. Liu, and D.J. McClements. 2018. Improving curcumin solubility and bioavailability by encapsulation in saponin-coated curcumin nanoparticles prepared using a simple pH-driven loading method. Food & Function 9: 1829–1839.CrossRef Peng, S., Z. Li, L. Zou, W. Liu, C. Liu, and D.J. McClements. 2018. Improving curcumin solubility and bioavailability by encapsulation in saponin-coated curcumin nanoparticles prepared using a simple pH-driven loading method. Food & Function 9: 1829–1839.CrossRef
Metadata
Title
Acute Lung Injury: IL-17A-Mediated Inflammatory Pathway and Its Regulation by Curcumin
Authors
Mahesh Manjunath Gouda
Yashodhar Prabhakar Bhandary
Publication date
01-08-2019
Publisher
Springer US
Published in
Inflammation / Issue 4/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-019-01010-4

Other articles of this Issue 4/2019

Inflammation 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine